Motivated by the previous findings, we conducted a phase IB clinical trial in patients with advanced TNBC that showed hyperactivation of CDK6 and/or MEK in their tumor samples, aiming to study a potentially powerful, orally available drug combination and biomarkers for this disease. This evidence concerns the gene CDK6 and neoplasm.